```html

Koch’s Bacillus Infection (Tuberculosis)

What is Koch's bacillus infection (Tuberculosis)?

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis, historically known as “Koch’s bacillus” after the German physician Robert Koch who identified it in 1882. The organism is a slow‑growing, aerobic, acid‑fast rod that primarily attacks the lungs (pulmonary TB) but can involve virtually any organ (extrapulmonary TB). TB spreads through aerosolized droplets expelled when a person with active pulmonary disease coughs, sneezes, speaks, or sings. Most exposures result in either no infection or a latent, asymptomatic state; however, about 5‑10 % of infected individuals develop active disease during their lifetime, especially when immunity wanes.

Because TB can mimic many other conditions and because it remains one of the top 10 causes of death worldwide, early recognition and appropriate management are crucial. The following sections outline the most common causes, associated symptoms, diagnostic steps, treatment options, and prevention measures, with clear guidance on when to seek professional care.

Common Causes

TB infection itself is caused by inhalation of M. tuberculosis bacilli, but several factors increase the risk of progressing from latent infection to active disease. The most important contributors include:

• Close contact with a person who has active pulmonary TB – household members, coworkers, or classmates.
• HIV infection or other conditions that markedly suppress immunity – the risk of active TB is 20‑30 times higher in people living with HIV.
• Diabetes mellitus – hyperglycemia impairs macrophage function, raising TB risk by 2‑3 fold.
• Chronic kidney disease or dialysis – uremia reduces immune surveillance.
• Use of immunosuppressive medications such as corticosteroids, TNF‑α inhibitors (e.g., infliximab, adalimumab), and biologic agents for autoimmune diseases.
• Malnutrition or low body weight – protein‑energy deficiency diminishes cell‑mediated immunity.
• Substance abuse – especially alcohol dependence and illicit drug use, which impair lung defenses.
• Silicosis or other occupational lung diseases – silica dust impairs macrophage killing of mycobacteria.
• Recent immigration from or travel to high‑TB‑burden regions – Asia, Africa, Eastern Europe, and parts of Latin America.
• Age extremes – infants and the elderly have weaker immune responses.

Associated Symptoms

Symptoms vary dramatically between latent infection (asymptomatic) and active disease. When TB becomes active, the clinical picture often includes a combination of the following:

• Persistent cough lasting ≥ 2 weeks, sometimes producing sputum or blood (hemoptysis).
• Unexplained weight loss (often > 10 % of body weight).
• Night sweats – drenching sweats that soak clothing and bedding.
• Fever – low‑grade (often 37.5–38.5 °C) that may be intermittent.
• Fatigue and weakness – a generalized sense of exhaustion.
• Chest pain – pleuritic in nature, worsened by deep breathing.
• Loss of appetite and generalized malaise.
• Extrapulmonary manifestations (when TB spreads beyond the lungs):
  • Lymphadenopathy (enlarged lymph nodes), especially cervical (“scrofula”).
  • Spinal pain and deformity (Pott disease).
  • Abdominal pain, ascites, or intestinal obstruction.
  • Renal symptoms such as hematuria.
  • Neurological signs if meninges are involved (TB meningitis).

Because many of these signs overlap with other respiratory infections, a high index of suspicion is required, especially in at‑risk populations.

When to See a Doctor

Prompt medical evaluation is essential if you experience any of the following:

• Cough that persists longer than two weeks, especially if it’s productive or bloody.
• Unexplained fever, night sweats, or weight loss.
• Persistent chest pain or shortness of breath.
• Swollen lymph nodes that do not resolve within a few weeks.
• History of close contact with a known TB case, recent travel to a high‑risk area, or a positive TB skin test/IGRA without prior treatment.
• Symptoms of meningitis (severe headache, neck stiffness, confusion) or spinal pain with neurologic deficits – these require emergency care.

Diagnosis

Diagnosing TB involves a combination of clinical assessment, imaging, and microbiologic testing.

1. Medical History and Physical Examination

Physicians ask about exposure risk, travel, immunosuppression, and symptom duration, and they perform a thorough lung and lymph‑node exam.

2. Tuberculin Skin Test (TST) or Interferon‑γ Release Assays (IGRA)

• TST (Mantoux test) – intradermal injection of purified protein derivative; induration ≥ 5 mm (high‑risk) or ≥ 10 mm (moderate risk) is considered positive.
• IGRAs (e.g., QuantiFERON‑TB Gold, T‑Spot) – blood tests that measure interferon‑γ response to TB‑specific antigens; they are not affected by prior BCG vaccination.

3. Chest Radiography

A postero‑anterior (PA) chest X‑ray can reveal classic findings such as upper‑lobe infiltrates, cavitary lesions, or hilar lymphadenopathy. However, a normal X‑ray does not exclude TB, especially in early disease or in immunocompromised patients.

4. Microbiologic Confirmation

• Sputum smear microscopy – acid‑fast bacilli (AFB) staining, rapid but less sensitive.
• Sputum culture – gold standard; grows M. tuberculosis on solid (Lowenstein‑Jensen) or liquid media (MGIT). Results take 2‑8 weeks.
• Nucleic acid amplification tests (NAAT) – e.g., GeneXpert MTB/RIF, provides results in < 2 hours and detects rifampicin resistance.
• Bronchoscopy or CT‑guided biopsy – for patients unable to produce sputum or with extrapulmonary disease.

5. Drug‑Resistance Testing

Phenotypic susceptibility testing and molecular assays (e.g., line‑probe assays) identify multidrug‑resistant (MDR) or extensively drug‑resistant (XDR) strains, directing appropriate therapy.

Treatment Options

Treatment aims to eradicate the bacteria, prevent relapse, and limit transmission. Regimens differ for drug‑susceptible, MDR, and XDR TB.

1. Drug‑Susceptible Pulmonary TB

World Health Organization (WHO) and CDC recommend a 6‑month regimen:

• Intensive phase (2 months): Isoniazid (INH) + Rifampin (RIF) + Pyrazinamide (PZA) + Ethambutol (EMB).
• Continuation phase (4 months): Isoniazid + Rifampin.

All drugs are taken daily or three times weekly under direct‑observed therapy (DOT) when feasible.

2. Latent TB Infection (LTBI)

People with a positive test but no active disease are offered preventive therapy to reduce the risk of future activation. Options include:

• Isoniazid daily for 6–9 months.
• Rifampin daily for 4 months.
• Isoniazid + Rifapentine once weekly for 12 weeks (3HP regimen).

3. Drug‑Resistant TB

For MDR‑TB (resistant to at least INH and RIF) and XDR‑TB, treatment duration extends to 18‑24 months and involves second‑line drugs such as fluoroquinolones, injectables (amikacin, capreomycin), and newer agents (bedaquiline, delamanid). Management should be guided by an experienced TB specialist and a drug‑susceptibility profile.

4. Supportive & Home Care

• Nutrition: Adequate calories and protein help restore immunity; supplementation with vitamin D may be beneficial.
• Hydration: Maintain fluid intake, especially if fever or night sweats are present.
• Rest: Sufficient sleep supports recovery.
• Adherence tools: Pill boxes, reminder apps, and family support improve completion rates.
• Infection control at home: Keep windows open, use fans to improve ventilation, and wear a surgical mask when coughing.

Prevention Tips

Because TB is contagious, public‑health measures are essential, alongside personal steps:

• Vaccination: Bacillus Calmette‑Guérin (BCG) vaccine provides protection against severe forms of pediatric TB; its effectiveness in adults varies.
• Screen high‑risk groups: Annual TST or IGRA for healthcare workers, people with HIV, and close contacts of TB cases.
• Prompt treatment of active cases: Successful therapy renders patients non‑infectious after ~2 weeks of adequate therapy.
• Environmental controls: In congregate settings (prisons, shelters), ensure adequate ventilation, UV germicidal lamps, and use of N‑95 respirators for staff.
• Healthy lifestyle: Good nutrition, smoking cessation, limiting alcohol, and managing chronic diseases lower susceptibility.
• Travel precautions: If traveling to high‑burden areas, avoid prolonged close contact with persons coughing, and consider pre‑travel screening if immunocompromised.

Emergency Warning Signs

Key Take‑aways

• Tuberculosis is caused by Mycobacterium tuberculosis and spreads through airborne droplets.
• Risk factors include HIV, diabetes, immunosuppressive therapy, malnutrition, and close contact with an infectious case.
• Typical symptoms are a persistent cough, fever, night sweats, weight loss, and fatigue; extrapulmonary disease can affect many organs.
• Seek medical care promptly for any prolonged cough, unexplained systemic symptoms, or known exposure.
• Diagnosis combines skin or blood tests, chest imaging, and microbiologic confirmation (smear, culture, NAAT).
• Standard treatment for drug‑susceptible TB is 6 months of multiple antibiotics; latent infection is treated with shorter regimens to prevent disease.
• Prevention relies on vaccination, early detection, effective treatment, and public‑health infection‑control measures.
• Red‑flag emergency signs such as massive hemoptysis, severe dyspnea, or meningitis symptoms require immediate emergency care.

For the most up‑to‑date recommendations, consult reputable sources such as the CDC, World Health Organization, Mayo Clinic, and the NIH National Institute of Allergy & Infectious Diseases.

```